F-Star Therapeutics FSTX shares are trading higher after the company entered into an exclusive licensing agreement with AstraZeneca AZN for its STING Inhibitors.
Under the agreement, AstraZeneca will receive global rights to research, develop and commercialize STING inhibitor compounds. F-Star is eligible for upfront and near-term payments of up to $12 million and potential milestone payments of over $300 million.
F-star Therapeutics Inc. is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies that seek to block tumor immune evasion in order to offer patients greater and more durable benefits than current immuno-oncology treatments.
At the time of publication, shares of F-Star Therapeutics were trading 12.0% higher at $8.22. The stock has a 52-week low of $7.75 and a 52-week high of $8.41.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
